<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>3987</id>
    <completedYear/>
    <publishedYear>2021</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>14</pageNumber>
    <edition/>
    <issue/>
    <volume>19</volume>
    <articleNumber>245</articleNumber>
    <type>article</type>
    <publisherName>BioMed Central</publisherName>
    <publisherPlace>London</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-09-22</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Translational precision medicine: an industry perspective</title>
    <abstract language="eng">In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective.</abstract>
    <parentTitle language="eng">Journal of Translational Medicine</parentTitle>
    <identifier type="issn">1479-5876</identifier>
    <identifier type="urn">urn:nbn:de:bvb:573-39873</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://creativecommons.org/licenses/by/4.0</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">SubjectUncontrolled_1,SubjectUncontrolled_2,PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PersonAuthorFirstName_6,PersonAuthorLastName_6,PersonAuthorFirstName_7,PersonAuthorLastName_7,PersonAuthorFirstName_8,PersonAuthorLastName_8,PersonAuthorFirstName_9,PersonAuthorLastName_9,PersonAuthorFirstName_10,PersonAuthorLastName_10,PersonAuthorFirstName_11,PersonAuthorLastName_11,PersonAuthorFirstName_12,PersonAuthorLastName_12,PersonAuthorFirstName_13,PersonAuthorLastName_13,PersonAuthorFirstName_14,PersonAuthorLastName_14,PublisherName,TitleMain_1,Language,TitleAbstract_1,TitleParent_1,ArticleNumber,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1186/s12967-021-02910-6</enrichment>
    <enrichment key="THI_openaccess">ja</enrichment>
    <enrichment key="THI_review">peer-review</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <licence>Creative Commons BY 4.0</licence>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <author>
      <first_name>Valeria</first_name>
      <last_name>de Luca</last_name>
    </author>
    <author>
      <first_name>Anna</first_name>
      <last_name>Kostikova</last_name>
    </author>
    <author>
      <first_name>Jason</first_name>
      <last_name>Laramie</last_name>
    </author>
    <author>
      <first_name>Scott</first_name>
      <last_name>Kennedy</last_name>
    </author>
    <author>
      <first_name>Enrico</first_name>
      <last_name>Ferrero</last_name>
    </author>
    <author>
      <first_name>Richard</first_name>
      <last_name>Siegel</last_name>
    </author>
    <author>
      <first_name>Martin</first_name>
      <last_name>Fink</last_name>
    </author>
    <author>
      <first_name>Sohail</first_name>
      <last_name>Ahmed</last_name>
    </author>
    <author>
      <first_name>John</first_name>
      <last_name>Millholland</last_name>
    </author>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <author>
      <first_name>Luca</first_name>
      <last_name>Piali</last_name>
    </author>
    <author>
      <first_name>Adrian</first_name>
      <last_name>Roth</last_name>
    </author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Translational medicine</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Precision medicine</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Drug development</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Biomarkers</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Multi-omics</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Modeling</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Artificial intelligence</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Pharmaceutical industry</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Digital biomarkers</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Companion diagnostics</value>
    </subject>
    <collection role="open_access" number="">open_access</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
    <thesisPublisher>Technische Hochschule Ingolstadt</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-haw/files/3987/s12967-021-02910-6.pdf</file>
  </doc>
  <doc>
    <id>3984</id>
    <completedYear/>
    <publishedYear>2022</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>177</pageFirst>
    <pageLast>178</pageLast>
    <pageNumber/>
    <edition/>
    <issue>3</issue>
    <volume>22</volume>
    <articleNumber/>
    <type>article</type>
    <publisherName>Springer Nature</publisherName>
    <publisherPlace>London</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">The significance of blockbusters in the pharmaceutical industry</title>
    <parentTitle language="eng">Nature Reviews Drug Discovery</parentTitle>
    <identifier type="issn">1474-1784</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T08:00:00Z","timestamp":1695024000508},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1038\/d41573-022-00213-z","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T17:06:28Z","timestamp":1670864788000},"page":"177-178","source":"Crossref","is-referenced-by-count":3,"title":["The significance of blockbusters in the pharmaceutical industry"],"prefix":"10.1038","volume":"22","author":[{"given":"Alexander","family":"Schuhmacher","sequence":"first","affiliation":[]},{"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[]},{"given":"Nikolaj","family":"Boger","sequence":"additional","affiliation":[]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Gassmann","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,12,12]]},"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/d41573-022-00213-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/d41573-022-00213-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/d41573-022-00213-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T14:05:57Z","timestamp":1677852357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/d41573-022-00213-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["CM23814110"],"URL":"http:\/\/dx.doi.org\/10.1038\/d41573-022-00213-z","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":["Drug Discovery","Pharmacology","General Medicine"],"published":{"date-parts":[[2022,12,12]]}}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://www.springernature.com/gp/researchers/text-and-data-mining</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">SubjectUncontrolled_1,SubjectUncontrolled_2,SubjectUncontrolled_3,PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PublisherName,TitleMain_1,Language,TitleParent_1,PageNumber,PageFirst,PageLast,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1038/d41573-022-00213-z</enrichment>
    <enrichment key="THI_openaccess">nein</enrichment>
    <enrichment key="THI_review">editorial review</enrichment>
    <enrichment key="THI_DownloadUrl">https://www.nature.com/magazine-assets/d41573-022-00213-z/23814366</enrichment>
    <enrichment key="THI_DownloadUrl">https://www.nature.com/magazine-assets/d41573-022-00213-z/23814364</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <author>
      <first_name>Nikolaj</first_name>
      <last_name>Boger</last_name>
    </author>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <author>
      <first_name>Oliver</first_name>
      <last_name>Gassmann</last_name>
    </author>
    <collection role="institutes" number="15986">THI Business School</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
  </doc>
  <doc>
    <id>4575</id>
    <completedYear/>
    <publishedYear>2022</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>1</pageFirst>
    <pageLast>6</pageLast>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <articleNumber/>
    <type>bookpart</type>
    <publisherName>Wiley-VCH</publisherName>
    <publisherPlace>Weinheim</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Biopharmaceutical Innovation at a Glance</title>
    <parentTitle language="eng">Principles of Biomedical Sciences and Industry: Translating Ideas into Treatments</parentTitle>
    <identifier type="isbn">978-3-527-34571-7</identifier>
    <identifier type="isbn">978-3-527-82401-4</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:03:37Z","timestamp":1692680617568},"edition-number":"1","reference-count":10,"publisher":"Wiley","isbn-type":[{"value":"9783527345717","type":"print"},{"value":"9783527824014","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,3]]},"DOI":"10.1002\/9783527824014.ch1","type":"other","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T21:37:43Z","timestamp":1658525863000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Biopharmaceutical Innovation at a Glance"],"prefix":"10.1002","author":[{"given":"Markus","family":"Hinder","sequence":"first","affiliation":[]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[]},{"given":"Alexander","family":"Schuhmacher","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"e_1_2_1_2_1","volume-title":"Papyrus Ebers","author":"No author"},{"key":"e_1_2_1_3_1","volume-title":"Papyrus Lahun","author":"No author"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.11.012"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5460.1960"},{"key":"e_1_2_1_6_1","unstructured":"ICH(n.d.).International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).https:\/\/www.ich.org\/(accessed 3 October 2020)."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.613"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0838-4"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.2.404"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2251"},{"key":"e_1_2_1_11_1","unstructured":"Waters R.andUrquhart L.(2019).Evaluate Pharma. World Preview Outlook to 2024.https:\/\/www.evaluate.com\/thought\u2010leadership\/pharma\/evaluatepharma\u2010world\u2010preview\u20102019\u2010outlook\u20102024(accessed 27 September 2020)."}],"container-title":["Principles of Biomedical Sciences and Industry"],"original-title":[],"link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/9783527824014.ch1","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/9783527824014.ch1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T03:54:12Z","timestamp":1692590052000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/9783527824014.ch1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"ISBN":["9783527345717","9783527824014"],"references-count":10,"alternative-id":["10.1002\/9783527824014.ch1","10.1002\/9783527824014"],"URL":"http:\/\/dx.doi.org\/10.1002\/9783527824014.ch1","archive":["Portico"],"relation":{},"published":{"date-parts":[[2022,7,22]]}}}</enrichment>
    <enrichment key="local_crossrefDocumentType">other</enrichment>
    <enrichment key="local_crossrefLicence">http://doi.wiley.com/10.1002/tdm_license_1.1</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PublisherName,TitleMain_1,TitleParent_1,PageNumber,PageFirst,PageLast,Edition,CompletedYear,IdentifierIsbn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1002/9783527824014.ch1</enrichment>
    <enrichment key="THI_openaccess">nein</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <editor>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </editor>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <editor>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </editor>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <editor>
      <first_name>Jörg</first_name>
      <last_name>Goldhahn</last_name>
    </editor>
    <editor>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </editor>
    <collection role="institutes" number="15986">THI Business School</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
  </doc>
  <doc>
    <id>5411</id>
    <completedYear/>
    <publishedYear>2021</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>2786</pageFirst>
    <pageLast>2793</pageLast>
    <pageNumber/>
    <edition/>
    <issue>12</issue>
    <volume>26</volume>
    <articleNumber/>
    <type>article</type>
    <publisherName>Elsevier</publisherName>
    <publisherPlace>Amsterdam</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Systematic risk identification and assessment using a new risk map in pharmaceutical R&amp;D</title>
    <parentTitle language="eng">Drug Discovery Today</parentTitle>
    <identifier type="issn">1878-5832</identifier>
    <identifier type="issn">1359-6446</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T01:10:52Z","timestamp":1722215452379},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.drudis.2021.06.015","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T15:17:54Z","timestamp":1625325474000},"page":"2786-2793","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Systematic risk identification and assessment using a new risk map in pharmaceutical R&amp;amp;D"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"http:\/\/orcid.org\/0000-0001-7884-5757","authenticated-orcid":false,"given":"Alexander","family":"Schuhmacher","sequence":"first","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-8681-7534","authenticated-orcid":false,"given":"Clara","family":"Brieke","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Gassmann","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-2293-8342","authenticated-orcid":false,"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.06.015_b0005","unstructured":"Waters RU, Urquhart L. EvaluatePharma. World Preview 2019, Outlook to 2024. London. Evaluate, 2019."},{"key":"10.1016\/j.drudis.2021.06.015_b0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&amp;D productivity: the pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.drudis.2021.06.015_b0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.drudis.2016.11.021","article-title":"Global vision of druggability issues: applications and perspectives","volume":"22","author":"Abi Hussein","year":"2017","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.drudis.2021.06.015_b0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrd.2017.232","article-title":"Automating drug discovery","volume":"17","author":"Schneider","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.drudis.2021.06.015_b0025","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nrd1904","article-title":"Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology","volume":"4","author":"van der Greef","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"7172","key":"10.1016\/j.drudis.2021.06.015_b0030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nature06526","article-title":"Reaching for high-hanging fruit in drug discovery at protein-protein interfaces","volume":"450","author":"Wells","year":"2007","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.drudis.2021.06.015_b0035","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.2174\/0929867324666171107101035","article-title":"The in silico drug discovery toolbox: applications in lead discovery and optimization","volume":"26","author":"Bruno","year":"2019","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/j.drudis.2021.06.015_b0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.drudis.2020.12.009","article-title":"Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet","volume":"26","author":"Bender","year":"2021","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.drudis.2021.06.015_b0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul","year":"2021","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.drudis.2021.06.015_b0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrd986","article-title":"A guide to drug discovery: target selection in drug discovery","volume":"2","author":"Knowles","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2021.06.015_b0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&amp;D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.drudis.2021.06.015_b0060","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.15252\/embr.201744876","article-title":"The reproducibility \u201ccrisis\u201d","volume":"18","author":"Hunter","year":"2017","journal-title":"EMBO Rep"},{"key":"10.1016\/j.drudis.2021.06.015_b0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41746-019-0079-z","article-title":"The reproducibility crisis in the age of digital medicine","volume":"2","author":"Stupple","year":"2019","journal-title":"NPJ Digit Med"},{"issue":"1","key":"10.1016\/j.drudis.2021.06.015_b0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2017.194","article-title":"Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications","volume":"17","author":"Shih","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"7787","key":"10.1016\/j.drudis.2021.06.015_b0075","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/d41586-019-03846-0","article-title":"Hunting for new drugs with AI","volume":"576","author":"Freedman","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.drudis.2021.06.015_b0080","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.clinthera.2015.12.001","article-title":"IBM Watson: how cognitive computing can be applied to big data challenges in life sciences research","volume":"38","author":"Chen","year":"2016","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.drudis.2021.06.015_b0085","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1039\/C9SC04336E","article-title":"Target identification among known drugs by deep learning from heterogeneous networks","volume":"11","author":"Zeng","year":"2020","journal-title":"Chem Sci"},{"issue":"7","key":"10.1016\/j.drudis.2021.06.015_b0090","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.drudis.2013.12.004","article-title":"Data-driven medicinal chemistry in the era of big data","volume":"19","author":"Lusher","year":"2014","journal-title":"Drug Discov Today"},{"issue":"7792","key":"10.1016\/j.drudis.2021.06.015_b0095","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-019-1923-7","article-title":"Improved protein structure prediction using potentials from deep learning","volume":"577","author":"Senior","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.drudis.2021.06.015_b0100","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41563-019-0332-5","article-title":"Opportunities and challenges using artificial intelligence in ADME\/Tox","volume":"18","author":"Bhhatarai","year":"2019","journal-title":"Nat Mater"},{"issue":"2","key":"10.1016\/j.drudis.2021.06.015_b0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cts.12538","article-title":"It's time to reverse our thinking: the reverse translation research paradigm","volume":"11","author":"Shakhnovich","year":"2018","journal-title":"Clin Transl Sci"},{"issue":"8","key":"10.1016\/j.drudis.2021.06.015_b0110","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tips.2019.05.005","article-title":"Artificial intelligence for clinical trial design","volume":"40","author":"Harrer","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2021.06.015_b0115","first-page":"1","article-title":"Computer-aided clinical trial recruitment based on domain-specific language translation: a case study of retinopathy of prematurity","volume":"2017","author":"Zhang","year":"2017","journal-title":"J Healthc Eng"},{"key":"10.1016\/j.drudis.2021.06.015_b0120","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1158\/1538-7445.AM2020-3382","article-title":"MatchMiner: an open-source computational platform for genomically-driven matching of cancer patients to precision medicine clinical trials","volume":"80","author":"Mazor","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2021.06.015_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8659460","article-title":"Therapy decision support based on recommender system methods","volume":"2017","author":"Gr\u00e4\u00dfer","year":"2017","journal-title":"J Healthc Eng"},{"issue":"9","key":"10.1016\/j.drudis.2021.06.015_b0130","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.drudis.2020.06.002","article-title":"The upside of being a digital pharma player","volume":"25","author":"Schuhmacher","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2021.06.015_b0135","doi-asserted-by":"crossref","first-page":"101603","DOI":"10.1016\/j.jddst.2020.101603","article-title":"Application of artificial intelligence in modeling of the doxorubicin release behavior of pH and temperature responsive poly(NIPAAm-co-AAc)-PEG IPN hydrogel","volume":"57","author":"Boztepe","year":"2020","journal-title":"J Drug Deliv Sci Tec"},{"issue":"9","key":"10.1016\/j.drudis.2021.06.015_b0140","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","article-title":"Deep learning enables rapid identification of potent DDR1 kinase inhibitors","volume":"37","author":"Zhavoronkov","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2021.06.015_b0145","doi-asserted-by":"crossref","unstructured":"Macaulay R, Cable G, Siddiqui MK, Lucas J. Synthetic control arms: hype versus reality, the payer perspective. Value Health 2020; 23: S758\u2013S758.","DOI":"10.1016\/j.jval.2020.08.2082"},{"issue":"2","key":"10.1016\/j.drudis.2021.06.015_b0150","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.2196\/mhealth.7030","article-title":"Use of a novel artificial intelligence platform on mobile devices to assess dosing compliance in a Phase 2 clinical trial in subjects with schizophrenia","volume":"5","author":"Bain","year":"2017","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.drudis.2021.06.015_b0155","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12874-020-01109-5","article-title":"Ensuring protocol compliance and data transparency in clinical trials using Blockchain smart contracts","volume":"20","author":"Omar","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.drudis.2021.06.015_b0160","first-page":"340","article-title":"Big data and pharmacovigilance: data mining for adverse drug events and interactions","volume":"43","author":"Ventola","year":"2018","journal-title":"P T"},{"issue":"3","key":"10.1016\/j.drudis.2021.06.015_b0165","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cpt.320","article-title":"The FDA's sentinel initiative\u2013a comprehensive approach to medical product surveillance","volume":"99","author":"Ball","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.drudis.2021.06.015_b0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1108\/EJMBE-12-2018-0139","article-title":"Innovations in intellectual property rights management their potential benefits and limitations","volume":"28","author":"Modic","year":"2019","journal-title":"Eur J Manag Bus Econ"},{"key":"10.1016\/j.drudis.2021.06.015_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drudis.2020.07.020","article-title":"The present and future of project management in pharmaceutical R&amp;D","volume":"26","author":"Schuhmacher","year":"2021","journal-title":"Drug Discov Today"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621002877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621002877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T16:19:59Z","timestamp":1680106799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621002877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1359644621002877"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.06.015","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic risk identification and assessment using a new risk map in pharmaceutical R&amp;D","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://www.elsevier.com/tdm/userlicense/1.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorIdentifierOrcid_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorIdentifierOrcid_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorIdentifierOrcid_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PublisherName,TitleMain_1,Language,TitleParent_1,PageNumber,PageFirst,PageLast,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_openaccess">nein</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1016/j.drudis.2021.06.015</enrichment>
    <enrichment key="THI_review">peer-review</enrichment>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Clara</first_name>
      <last_name>Brieke</last_name>
    </author>
    <author>
      <first_name>Oliver</first_name>
      <last_name>Gassmann</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
  </doc>
  <doc>
    <id>5638</id>
    <completedYear/>
    <publishedYear>2025</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>7</pageNumber>
    <edition/>
    <issue>2</issue>
    <volume>30</volume>
    <articleNumber>104291</articleNumber>
    <type>article</type>
    <publisherName>Elsevier</publisherName>
    <publisherPlace>Amsterdam</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>2025-02-04</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Benchmarking R&amp;D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006–2022)</title>
    <abstract language="eng">Previous analyses provide an industry benchmark of ∼10% for the success rate in clinical development. However, prior analyses were limited by a narrow timeframe, a diverse research focus, biases in phase-to-phase transition methodology or a focus on specific use cases. We calculated unbiased input:output ratios (Phase I to FDA new drug approval) to analyze the likelihood of first approval using data from clinicaltrials.gov, encompassing a total of 2092 active ingredients, 19 927 clinical trials conducted by 18 leading pharmaceutical companies (2006–2022) and 274 new drug approvals. Our study reveals an average likelihood of first approval rate of 14.3% across leading research-based pharmaceutical companies, broadly ranging from 8% to 23%.</abstract>
    <parentTitle language="eng">Drug Discovery Today</parentTitle>
    <identifier type="issn">1878-5832</identifier>
    <identifier type="urn">urn:nbn:de:bvb:573-56382</identifier>
    <note>Corrigendum verfügbar unter https://doi.org/10.1016/j.drudis.2025.104326</note>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://www.elsevier.com/tdm/userlicense/1.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PublisherName,TitleMain_1,Language,TitleParent_1,ArticleNumber,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1016/j.drudis.2025.104291</enrichment>
    <enrichment key="THI_openaccess">ja</enrichment>
    <enrichment key="THI_DownloadUrl">https://ars.els-cdn.com/content/image/1-s2.0-S1359644625000042-mmc1.docx</enrichment>
    <enrichment key="THI_review">peer-review</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <licence>Creative Commons BY 4.0</licence>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <author>
      <first_name>Elazar</first_name>
      <last_name>Brief</last_name>
    </author>
    <author>
      <first_name>Oliver</first_name>
      <last_name>Gassmann</last_name>
    </author>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <collection role="institutes" number="15986">THI Business School</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
    <thesisPublisher>Technische Hochschule Ingolstadt</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-haw/files/5638/1-s2.0-S1359644625000042-main.pdf</file>
  </doc>
  <doc>
    <id>5775</id>
    <completedYear/>
    <publishedYear>2025</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>9</pageNumber>
    <edition/>
    <issue>3</issue>
    <volume>30</volume>
    <articleNumber>104306</articleNumber>
    <type>article</type>
    <publisherName>Elsevier</publisherName>
    <publisherPlace>Amsterdam</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>2025-03-28</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">A case study assessing the impact of M&amp;A and licensing on FDA drug approvals of leading pharmaceutical companies</title>
    <abstract language="eng">Despite a recent increase in FDA new drug approvals, leading pharmaceutical companies continue to face R&amp;D productivity challenges. This highlights the need to better understand the context of their R&amp;D concepts and related R&amp;D outputs. Consequently, we conducted a systematic assessment of the impact of R&amp;D expenditures, R&amp;D intensities, mergers &amp; acquisitions (M&amp;A) deals and licensing agreements on new drug approvals of leading pharmaceutical companies between 2012 and 2021. Our analysis provides key insights into differentiating R&amp;D factors: whereas R&amp;D expenditures and the number of M&amp;A deals correlate with the number of new drug approvals, our analysis shows no correlation with R&amp;D intensity or the number of licensing agreements.</abstract>
    <parentTitle language="eng">Drug Discovery Today</parentTitle>
    <identifier type="issn">1878-5832</identifier>
    <identifier type="urn">urn:nbn:de:bvb:573-57756</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://www.elsevier.com/tdm/userlicense/1.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PublisherName,TitleMain_1,Language,TitleParent_1,ArticleNumber,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1016/j.drudis.2025.104306</enrichment>
    <enrichment key="THI_openaccess">ja</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <enrichment key="THI_review">peer-review</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>Creative Commons BY 4.0</licence>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Kyrylo</first_name>
      <last_name>Grinchenko</last_name>
    </author>
    <author>
      <first_name>Oliver</first_name>
      <last_name>Gassmann</last_name>
    </author>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <collection role="institutes" number="15986">THI Business School</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
    <thesisPublisher>Technische Hochschule Ingolstadt</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-haw/files/5775/1-s2.0-S1359644625000194-main.pdf</file>
  </doc>
  <doc>
    <id>4022</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>4</pageNumber>
    <edition/>
    <issue>11</issue>
    <volume>28</volume>
    <articleNumber>103789</articleNumber>
    <type>article</type>
    <publisherName>Elsevier</publisherName>
    <publisherPlace>Amsterdam</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Is the blockbuster imperative broken?</title>
    <parentTitle language="eng">Drug Discovery Today</parentTitle>
    <identifier type="issn">1878-5832</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T11:12:21Z","timestamp":1696504341734},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.drudis.2023.103789","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:41:24Z","timestamp":1695829284000},"page":"103789","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is the blockbuster imperative broken?"],"prefix":"10.1016","author":[{"ORCID":"http:\/\/orcid.org\/0000-0001-7884-5757","authenticated-orcid":false,"given":"Alexander","family":"Schuhmacher","sequence":"first","affiliation":[]},{"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[]},{"given":"Nikolaj","family":"Boger","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Gassmann","sequence":"additional","affiliation":[]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103789_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103726","article-title":"Analysis of pharma R&amp;D productivity \u2013 a new perspective needed","volume":"28","author":"Schuhmacher","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103789_b0010","first-page":"837","article-title":"Big pharma moves from \u201cblockbusters\u201d to \u201cniche busters\u201d","volume":"16","author":"Dolgin","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2023.103789_b0015","article-title":"Charities chief: \u201cPharma blockbusters are gone\u201d","author":"Cressey","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103789_b0020","article-title":"The significance of blockbusters in the pharmaceutical industry","author":"Schuhmacher","year":"2021","journal-title":"Nature Rev Drug Discov"},{"key":"10.1016\/j.drudis.2023.103789_b0025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/d41573-020-00061-9","article-title":"Developing blockbuster drugs: both nature and nurture","volume":"20","author":"Berghauser Pont","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2023.103789_b0030","article-title":"From blockbuster to \u201cnichebuster\u201d: how a flawed legislation helped create a new profit model for the drug industry","volume":"370","author":"Marselis","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2023.103789_b0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrd2923","article-title":"The 'big pharma' dilemma: develop new drugs or promote existing ones?","volume":"8","author":"Weiss","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2023.103789_b0040","unstructured":"Evaluate. Evaluate Pharma \u2013 World Preview 2021, Outlook 2026. Evaluate Pharma. 2021. https:\/\/www.evaluate.com\/thought-leadership\/pharma\/world-preview-2022-report. Published October 8, 2022. Accessed August 28, 2023."},{"issue":"21","key":"10.1016\/j.drudis.2023.103789_b0045","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1001\/jama.2022.5542","article-title":"Trends in prescription drug launch prices, 2008\u20132021","volume":"327","author":"Rome","year":"2022","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.drudis.2023.103789_b0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/d41573-021-00147-y","article-title":"Evolution of the market for mRNA technology [published correction appears in Nat Rev Drug Discov. 2021 Nov;20(11):880]","volume":"20","author":"Xie","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T19:53:56Z","timestamp":1696449236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623003057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":10,"alternative-id":["S1359644623003057"],"URL":"http:\/\/dx.doi.org\/10.1016\/j.drudis.2023.103789","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":["Drug Discovery","Pharmacology"],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is the blockbuster imperative broken?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103789"}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://www.elsevier.com/tdm/userlicense/1.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">SubjectUncontrolled_1,SubjectUncontrolled_2,PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorIdentifierOrcid_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PublisherName,TitleMain_1,Language,TitleParent_1,ArticleNumber,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1016/j.drudis.2023.103789</enrichment>
    <enrichment key="THI_openaccess">nein</enrichment>
    <enrichment key="THI_review">nein</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <author>
      <first_name>Nikolaj</first_name>
      <last_name>Boger</last_name>
    </author>
    <author>
      <first_name>Oliver</first_name>
      <last_name>Gassmann</last_name>
    </author>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <collection role="institutes" number="15986">THI Business School</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
  </doc>
  <doc>
    <id>5415</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>781</pageFirst>
    <pageLast>782</pageLast>
    <pageNumber/>
    <edition/>
    <issue>10</issue>
    <volume>22</volume>
    <articleNumber/>
    <type>article</type>
    <publisherName>Springer</publisherName>
    <publisherPlace>London</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Investigating the origins of recent pharmaceutical innovation</title>
    <parentTitle language="eng">Nature Reviews Drug Discovery</parentTitle>
    <identifier type="issn">1474-1784</identifier>
    <identifier type="issn">1474-1776</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:36:34Z","timestamp":1726446994418},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/d41573-023-00102-z","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T11:08:26Z","timestamp":1688555306000},"page":"781-782","source":"Crossref","is-referenced-by-count":5,"title":["Investigating the origins of recent pharmaceutical innovation"],"prefix":"10.1038","volume":"22","author":[{"given":"Alexander","family":"Schuhmacher","sequence":"first","affiliation":[]},{"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[]},{"given":"Alexander","family":"Dodel","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Gassmann","sequence":"additional","affiliation":[]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/d41573-023-00102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/d41573-023-00102-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/d41573-023-00102-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T13:02:11Z","timestamp":1695992531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/d41573-023-00102-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["CM25510056"],"URL":"https:\/\/doi.org\/10.1038\/d41573-023-00102-z","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]}}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://www.springernature.com/gp/researchers/text-and-data-mining</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PublisherName,TitleMain_1,Language,TitleParent_1,PageNumber,PageFirst,PageLast,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <enrichment key="THI_openaccess">nein</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1038/d41573-023-00102-z</enrichment>
    <enrichment key="THI_review">nein</enrichment>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Dodel</last_name>
    </author>
    <author>
      <first_name>Oliver</first_name>
      <last_name>Gassmann</last_name>
    </author>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <collection role="institutes" number="15986">THI Business School</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
  </doc>
  <doc>
    <id>3723</id>
    <completedYear/>
    <publishedYear>2022</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>2395</pageFirst>
    <pageLast>2405</pageLast>
    <pageNumber/>
    <edition/>
    <issue>9</issue>
    <volume>27</volume>
    <articleNumber/>
    <type>article</type>
    <publisherName>Elsevier</publisherName>
    <publisherPlace>Amsterdam</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Open innovation: A paradigm shift in pharma R&amp;D?</title>
    <parentTitle language="eng">Drug Discovery Today</parentTitle>
    <identifier type="issn">1878-5832</identifier>
    <enrichment key="THI_articleversion">published</enrichment>
    <enrichment key="THI_openaccess">nein</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1016/j.drudis.2022.05.018</enrichment>
    <enrichment key="THI_review">peer-review</enrichment>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Oliver</first_name>
      <last_name>Gassmann</last_name>
    </author>
    <author>
      <first_name>Doria</first_name>
      <last_name>Bieniok</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <collection role="institutes" number="15986">THI Business School</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
  </doc>
  <doc>
    <id>5005</id>
    <completedYear/>
    <publishedYear>2024</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>8</pageNumber>
    <edition/>
    <issue>9</issue>
    <volume>29</volume>
    <articleNumber>104128</articleNumber>
    <type>article</type>
    <publisherName>Elsevier</publisherName>
    <publisherPlace>Amsterdam</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>2024-08-20</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)</title>
    <abstract language="eng">This article addresses the research and development (R&amp;D) productivity challenge of the pharmaceutical industry, focusing on United States Food and Drug Administration (FDA)-related new drug approvals of the top 20 pharmaceutical companies (2014–2023). We evaluated the degree of innovation in new drugs to determine the innovativeness of these leading companies. A key finding of our analysis is the decline in the number of new drugs approved by the FDA for these leading companies over the investigated time period. This trend suggests that some of the leading companies are losing ground in R&amp;D innovation, raising concerns about their ability to sustain competitive advantage, ensure long-term market success, and maintain viable business models.</abstract>
    <parentTitle language="eng">Drug Discovery Today</parentTitle>
    <identifier type="issn">1878-5832</identifier>
    <identifier type="urn">urn:nbn:de:bvb:573-50058</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:23:06Z","timestamp":1723767786203},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.drudis.2024.104128","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:13:10Z","timestamp":1722888790000},"page":"104128","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of FDA approvals by top 20 pharma companies (2014\u20132023)"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"http:\/\/orcid.org\/0000-0001-7884-5757","authenticated-orcid":false,"given":"Alexander","family":"Schuhmacher","sequence":"first","affiliation":[]},{"given":"Oliver","family":"Gassmann","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-2293-8342","authenticated-orcid":false,"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104128_b0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&amp;D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/d41573-020-00059-3","article-title":"Breaking Eroom\u2019s Law","volume":"19","author":"Ringel","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-020-02313-z","article-title":"The endless frontier? The recent increase of R&amp;D productivity in pharmaceuticals","volume":"18","author":"Pammolli","year":"2020","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2024.104128_b0020","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-024-00068-6","article-title":"Efficiency, effectiveness and productivity in pharmaceutical R&amp;D","author":"Roland","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&amp;D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2478\/fman-2013-0004","article-title":"What is innovativeness: literature review","volume":"4","author":"Nasierowski","year":"2012","journal-title":"Found Manag"},{"key":"10.1016\/j.drudis.2024.104128_b0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1108\/14601060210415135","article-title":"Situations for innovation management: towards a contingency model","volume":"5","author":"Drejer","year":"2002","journal-title":"Eur J Innov Manag"},{"key":"10.1016\/j.drudis.2024.104128_b0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/01.JAC.0000304100.38120.b2","article-title":"Something new every day: defining innovation and innovativeness in drug therapy","volume":"31","author":"Aronson","year":"2008","journal-title":"J Ambul Care Manage"},{"key":"10.1016\/j.drudis.2024.104128_b0045","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/acsmedchemlett.0c00319","article-title":"Structural approach to assessing the innovativeness of new drugs finds accelerating rate of innovation","volume":"11","author":"Wills","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104128_b0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/clpt.2013.115","article-title":"Defining, \u201cinnovativeness\u201d in drug development: a systematic review","volume":"94","author":"Kesselheim","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104128_b0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1509\/jm.10.0494","article-title":"Firm innovativeness and its performance outcomes: a meta-analytic review and theoretical integration","volume":"76","author":"Rubera","year":"2012","journal-title":"J Mark"},{"key":"10.1016\/j.drudis.2024.104128_b0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.indmarman.2003.08.015","article-title":"Innovativeness: its antecedents and impact on business performance","volume":"33","author":"Hult","year":"2004","journal-title":"Ind Mark Manag"},{"key":"10.1016\/j.drudis.2024.104128_b0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1509\/jmkg.67.4.82.18687","article-title":"Sources and financial consequences of radical innovation: insights from pharmaceuticals","volume":"67","author":"Sorescu","year":"2003","journal-title":"J Mark"},{"key":"10.1016\/j.drudis.2024.104128_b0070","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrd4336","article-title":"The discovery of first-in-class drugs: origins and evolution","volume":"13","author":"Eder","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0075","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0190","article-title":"Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study","volume":"371","author":"Hwang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2024.104128_b0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2019.20288","article-title":"FDA approval and regulation of pharmaceuticals, 1983\u20132018","volume":"323","author":"Darrow","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2024.104128_b0085","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","article-title":"A decade of FDA-approved drugs (2010\u20132019): trends and future directions","volume":"64","author":"Brown","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104128_b0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","article-title":"A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act","volume":"18","author":"Fermaglich","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2024.104128_b0095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2021.12.010","article-title":"Achieving end-to-end success in the clinic: Pfizer\u2019s learnings on R&amp;D productivity","volume":"27","author":"Fernando","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.104128_b0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","article-title":"Impact of a five-dimensional framework on R&amp;D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd4454-c1","article-title":"A plan for sustainable funding for US biomedical research","volume":"14","author":"Hensley","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrd.2016.91","article-title":"Organizational effectiveness: a key to R&amp;D productivity","volume":"15","author":"Tollman","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0115","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.drudis.2012.05.007","article-title":"Drug discovery in pharmaceutical industry: productivity challenges and trends","volume":"17","author":"Khanna","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.104128_b0120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2024.104128_b0125","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/d41586-024-01426-5","article-title":"How antibody-drug conjugates aim to take down cancer","volume":"629","author":"Plackett","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104128_b0130","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104128_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2024.104128_b0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nchembio.581","article-title":"Getting pharmaceutical R&amp;D back on target","volume":"7","author":"Bunnage","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2024.104128_b0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0155","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drudis.2016.08.009","article-title":"The many roles of molecular complexity in drug discovery","volume":"22","author":"M\u00e9ndez-Lucio","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.104128_b0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.255","article-title":"Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications","volume":"17","author":"Shih","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0165","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrd4725","article-title":"Why is it hard to terminate failing projects in pharmaceutical R&amp;D?","volume":"14","author":"Peck","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0170","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/d41573-023-00048-2","article-title":"First-in-class versus best-in-class: an update for new market dynamics","volume":"22","author":"Spring","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0175","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&amp;D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/d41573-021-00018-6","article-title":"The breast cancer drug market","volume":"20","author":"Wilcock","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/d41573-021-00054-2","article-title":"The oncology market for antibody-drug conjugates","volume":"20","author":"do Pazo","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0195","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrd4650","article-title":"Improving R&amp;D productivity","volume":"14","author":"Smietana","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0200","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tips.2018.03.003","article-title":"Orphan drugs and their impact on pharmaceutical development","volume":"39","author":"Attwood","year":"2018","journal-title":"Trends Pharmacol Sci"},{"year":"2012","series-title":"Allies in rare diseases: rare disease facts","author":"Global Genes","key":"10.1016\/j.drudis.2024.104128_b0205"},{"key":"10.1016\/j.drudis.2024.104128_b0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cts.12500","article-title":"International Rare Diseases Research Consortium (IRDiRC). Future of rare diseases research 2017\u20132027: an IRDiRC perspective","volume":"11","author":"Austin","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2024.104128_b0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/smj.4250131009","article-title":"Core capabilities and core rigidities: a paradox in managing new product development","volume":"13","author":"Leonard-Barton","year":"1992","journal-title":"Strateg Manag J"},{"key":"10.1016\/j.drudis.2024.104128_b0220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2307\/2393553","article-title":"Absorptive capacity: a new perspective on learning and innovation","volume":"35","author":"Cohen","year":"1990","journal-title":"Adm Sci q"},{"key":"10.1016\/j.drudis.2024.104128_b0225","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.technovation.2012.01.004","article-title":"The alliance innovation performance of R&amp;D alliances\u2014the absorptive capacity perspective","volume":"32","author":"Lin","year":"2012","journal-title":"Technovation"},{"key":"10.1016\/j.drudis.2024.104128_b0230","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.respol.2008.10.023","article-title":"Absorptive capacity and the search for innovation","volume":"38","author":"Fabrizio","year":"2009","journal-title":"Res Policy"},{"key":"10.1016\/j.drudis.2024.104128_b0235","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/(SICI)1097-0266(199708)18:7&lt;509::AID-SMJ882&gt;3.0.CO;2-Z","article-title":"Dynamic capabilities and strategic management","volume":"18","author":"Teece","year":"1997","journal-title":"Strateg Manag J"},{"key":"10.1016\/j.drudis.2024.104128_b0240","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/1097-0266(200010\/11)21:10\/11&lt;1105::AID-SMJ133&gt;3.0.CO;2-E","article-title":"Dynamic capabilities: what are they?","volume":"21","author":"Eisenhardt","year":"2000","journal-title":"Strateg Manag J"},{"key":"10.1016\/j.drudis.2024.104128_b0245","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/smj.640","article-title":"Explicating dynamic capabilities: the nature and microfoundations of (sustainable) enterprise performance","volume":"28","author":"Teece","year":"2007","journal-title":"Strateg Manag J"},{"year":"2007","series-title":"Dynamic capabilities: understanding strategic change in organizations","author":"Helfat","key":"10.1016\/j.drudis.2024.104128_b0250"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T03:33:33Z","timestamp":1723692813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1359644624002538"],"URL":"http:\/\/dx.doi.org\/10.1016\/j.drudis.2024.104128","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of FDA approvals by top 20 pharma companies (2014\u20132023)","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104128"}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://www.elsevier.com/tdm/userlicense/1.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorIdentifierOrcid_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorIdentifierOrcid_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PublisherName,TitleMain_1,Language,TitleParent_1,ArticleNumber,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1016/j.drudis.2024.104128</enrichment>
    <enrichment key="THI_review">peer-review</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <enrichment key="THI_openaccess">ja</enrichment>
    <licence>Creative Commons BY 4.0</licence>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Oliver</first_name>
      <last_name>Gassmann</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <collection role="institutes" number="15986">THI Business School</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
    <thesisPublisher>Technische Hochschule Ingolstadt</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-haw/files/5005/1-s2.0-S1359644624002538-main.pdf</file>
  </doc>
</export-example>
